# US 2011/0256060 A1 · Monoclonal antibody and its use for the identification of the oncofetal isoform of fibronectin (b-fn) for diagnosis or therpay

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0256060 A1
- Document ID: US20110256060A1
- Status: Published application
- Kind: A1
- Application number: 13/139,112
- Filed: 2009-12-11
- Published: 2011-10-20
- Earliest claimed: 2008-12-12
- Assignees: Sirius-Biotech S.R.L.
- Inventors: Patrizia Castellani; Francessa Sassi; M. Barbara Carnemolla; Laura Borsi; Enrica Balza
- Web page: https://patentgrep.com/patent/US20110256060A1

## CPC

- C07K 16/18: against material from animals or humans
- A61P 35/00: Antineoplastic agents
- A61K 2039/505: {comprising antibodies}
- C07K 2317/30: characterized by aspects of specificity or valency
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Epitopes localized on FNIII-8 repeat that are normally cryptic but are unmasked by insertion of FNIII-B into the FN molecule and are recognized by specific ligands are described; antibodies or their fragments able to identify the above said Cepitope are also described.

## Claims

### Claim at position 1

1-8. (canceled)

### Claim 9

An isolated peptide epitope which consists of an amino acid sequence which is found in a fibronectin III-8 repeat, wherein said peptide epitope is cryptic but is unmasked upon insertion of fibronectin III-B into a fibronectin molecule.

### Claim 10

An isolated antibody which binds specifically to a peptide epitope which consists of an amino acid sequence which is found in a fibronectin III-8 repeat, wherein said peptide epitope is cryptic but is unmasked upon insertion of fibronectin III-B into a fibronectin molecule, or a binding fragment thereof.

### Claim 11 (depends on 10)

The isolated antibody or binding fragment, or a binding fragment thereof of claim 10, wherein said antibody is a monoclonal antibody.

### Claim 12 (depends on 10)

The isolated antibody or binding fragment of claim 10, comprising a VH region encoded by SEQ ID NO: 5, and a VLK region encoded by SEQ ID NO: 6.

### Claim 13 (depends on 11)

Hybridoma cell line which produces the monoclonal antibody of claim 11.

### Claim 14 (depends on 10)

A conjugate of the isolated antibody or binding fragment of claim 10 and a diagnostic or therapeutically active molecule.

### Claim 15 (depends on 12)

A conjugate of the isolated antibody or binding fragment of claim 12 and a diagnostic or therapeutically active molecule.

### Claim 16 (depends on 14)

The conjugate of claim 14, wherein said diagnostic molecule is a fluorescent molecule or a radioactive isotope.

### Claim 17 (depends on 15)

The conjugate of claim 15, wherein said diagnostic molecule is a fluorescent molecule or a radioactive isotope.

### Claim 18 (depends on 14)

The conjugate of claim 14, wherein said therapeutically active molecule is a radioactive isotope, a cytokine, or a chemotherapeutic agent.

### Claim 19 (depends on 15)

The conjugate of claim 15, wherein said therapeutically active molecule is a radioactive isotope, a cytokine, or a chemotherapeutic agent.

### Claim 20 (depends on 10)

A method for determining a fibronectin isoform which contains a fibronectin III-B domain, comprising contacting a sample with the antibody or binding fragment of claim 10, and determining binding as an indication of presence of said fibronectin isoform.

### Claim 21 (depends on 20)

The method of claim 20, wherein said sample is a biological fluid.

### Claim 22 (depends on 20)

The method of claim 20, wherein said sample is a tissue.

### Claim 23 (depends on 10)

A method for treating a disorder characterized by expression of a fibronectin isoform which includes a fibronectin III-B domain, comprising administering an amount of the isolated antibody or binding fragment of claim 10 to a subject in need thereof, in an amount sufficient to alleviate said disorder.

### Claim 24 (depends on 14)

A method for treating a disorder characterized by expression of a fibronectin isoform which includes a fibronectin III-B domain, comprising administering an amount of the conjugate of claim 14 to a subject in need thereof, in an amount sufficient to alleviate said disorder.

### Claim 25 (depends on 23)

The method of claim 23, wherein said disorder is a neoplastic disorder.

### Claim 26 (depends on 24)

The method of claim 24, wherein said disorder is a neoplastic disorder.
